Skip to main content
Retour
Watch Compare

CUMBERLAND PHARMACEUTICALS INC

Qualité des données : 100%
CPIX
NASDAQ Manufacturing Chemicals
3,09 €
▼ 0,02 € (-0,64%)
Cap. Boursière: 46,22 M
Prix
3,09 €
Cap. Boursière
46,22 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Revenue grew 5,47% annually over 5 years — modest growth
Generating 4,83 M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 12,10%
Capital efficient — spends only 0,22% of revenue on capex

Croissance

Revenue Growth (5Y)
5,47%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)17,57%
Earnings (1Y)N/A
FCF Growth (3Y)-8,80%

Qualité

Return on Equity
-10,48%
Au-dessus de la moyenne du secteur (-53,58%)
ROIC-5,16%
Net Margin-6,37%
Op. Margin-6,27%

Sécurité

Debt / Equity
N/A
Current Ratio1,23
Interest Coverage-5,63

Valorisation

PE (TTM|NTM)
-16,30 | 22,07
En dessous de la moyenne du secteur (-1,48)
P/B Ratio1,77
EV/EBITDA22,92
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1366 pairs)
Métrique Action Médiane du Secteur
P/E -16,3 -1,5
P/B 1,8 1,6
ROE % -10,5 -53,6
Net Margin % -6,4 -41,5
Rev Growth 5Y % 5,5 1,8
D/E — 0,3

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Aucune estimation prévisionnelle disponible

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q22021 -0,07 € 0,00 € +98,4%
Q12021 -0,07 € 0,07 € +200,0%
Q42020 -0,01 € 0,01 € +200,0%
Q32020 -0,07 € 0,02 € +128,6%

ETFs Holding This Stock

BRUSX BRUSX
0,60% weight
BRSIX BRSIX
0,22% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 17,57% Revenue Growth (3Y) 6,10%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 5,47% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 44,52 M Net Income (TTM) -2,84 M
ROE -10,48% ROA -4,24%
Gross Margin N/A Operating Margin -6,27%
Net Margin -6,37% Free Cash Flow (TTM) 4,83 M
ROIC -5,16% FCF Growth (3Y) -8,80%
Safety
Debt / Equity N/A Current Ratio 1,23
Interest Coverage -5,63 Asset Turnover 0,67
Working Capital 5,63 M Tangible Book Value 10,20 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -16,30 Forward P/E 22,07
P/B Ratio 1,77 P/S Ratio 1,04
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 22,92 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield 4,53%
FCF Yield 10,46%
Market Cap 46,22 M Enterprise Value 31,02 M
Per Share
EPS (Diluted TTM) -0,19 Revenue / Share 2,98
FCF / Share 0,32 OCF / Share 0,33
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,22% FCF Conversion -170,47%
SBC-Adj. FCF 4,52 M Growth Momentum 12,10

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 44,52 M 37,87 M 39,55 M 42,01 M 35,99 M
Net Income -2,84 M -6,48 M -6,28 M -5,57 M -3,51 M
EPS (Diluted) -0,19 -0,46 -0,44 -0,38 -0,24
Gross Profit — — — — —
Operating Income -2,79 M -6,43 M -9,55 M -5,70 M -7,68 M
EBITDA — — — — —
R&D Expenses 5,57 M 4,82 M 5,83 M 6,69 M 5,68 M
SG&A Expenses — — — — —
D&A 4,15 M 4,90 M 4,94 M 5,33 M 4,61 M
Interest Expense 495 990,0 605 508,0 667 861,0 585 995,0 98 031,0
Income Tax 40 256,0 -22 669,0 45 769,0 68 850,0 34 891,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 76,82 M 75,58 M 81,78 M 92,93 M 84,46 M
Total Liabilities 52,28 M 53,04 M 52,52 M 56,95 M 41,86 M
Shareholders' Equity 24,88 M 22,85 M 29,60 M 36,27 M 42,81 M
Total Debt — — — — —
Cash & Equivalents 11,44 M 17,96 M 18,32 M 19,76 M 27,04 M
Current Assets 37,06 M 36,45 M 35,71 M 45,87 M 45,69 M
Current Liabilities 36,74 M 31,62 M 27,98 M 28,58 M 19,28 M